title: Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients.
abstract: Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have been reported in a study on newborns and in a few reports on children and adolescents. However, thrombotic complications can be as severe in children as they are in adults. In the case of HIT II, the withdrawal of heparin is required and alternative anticoagulation should be started. In contrast to numerous investigations in adult patients, including prospective studies, experience with alternative anticoagulants in pediatric patients is limited. The available data were analyzed according to HIT II complications, alternative anticoagulation, and clinical outcome. In conclusion, HIT II represents a potentially dangerous complication of heparin therapy in pediatric patients also. Alternative anticoagulation applied in pediatric patients mainly included danaparoid sodium and recombinant hirudin. In most patients treated with these anticoagulants, effective anticoagulation and clinical improvement were observed. Because of limited experience, more data are required for optimal management of HIT II in young patients.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Severin
authors.forename: Barbara
authors.initials: B
authors.lastname: Zieger
authors.forename: Anton H
authors.initials: AH
authors.lastname: Sutor
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000494:pharmacology*; D002648:Child; D002809:Chondroitin Sulfates / Q000494:pharmacology*; D003871:Dermatan Sulfate / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006493:Heparin / Q000009:adverse effects* / Q000494:pharmacology; D006497:Heparan Sulfate / Q000494:pharmacology*; D024764:Hirudin Therapy; D006629:Hirudins / Q000494:pharmacology*; D006801:Humans; D008297:Male; D013927:Thrombosis / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; C035838:danaparoid